Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Study ID
NCT06766019
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This trial is a prospective, single-arm, single-center, phase II clinical study, mainly targeting subjects with locally advanced pancreatic cancer, to explore the efficacy and safety of adebrelimab combined with irinotecan liposome (II), oxaliplatin, and 5-FU/LV conversion in the treatment of locally advanced pancreatic cancer.

Key Dates

Start date
Oct 16, 2024
Status verified
Jan 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
47 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
    Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

Primary Outcome Measure

Surgical conversion rate [ Time Frame: Up to 6 months ]

Related Studies